Table 1.
Clinical and demographic features of the studied subjects
|
Characteristics |
SLE patients |
Healthy controls |
|
|---|---|---|---|
| Pre-treatment | Post-treatment | ||
| No. of cases |
40 |
40 |
40 |
| Female, n (%) |
36 (90.0%) |
36 (90.0%) |
36 (90.0%) |
| Male, n (%) |
4 (10%) |
4 (10%) |
4 (10%) |
| Age, years (range) |
33.7 (20 ~ 55) |
33.7 (20 ~ 55) |
34.8 (21 ~ 57) |
| Course of disease months |
11.2 (1 ~ 26) |
12.2 (2 ~ 27) |
- |
| (range) | |||
| SLEDAI (mean ± SD) |
11.45 ± 3.76 |
7.90 ± 4.00 |
- |
| Skin and mucosa lesion |
28 (70.0%) |
15 (37.5%0) |
- |
| Serositis, n (%) |
15 (37.5%) |
8 (20.0%) |
- |
| Arthritis, n (%) |
18 (45.0%) |
4 (10.0%) |
- |
| Lupus nephritis, n (%) |
24 (60.0%) |
20 (50%) |
- |
| Hematologic involvement |
25 (62.5%) |
9 (22.5%) |
- |
| NPSLE, n (%) |
1 (2.5%) |
0 |
- |
| ANA, n (%) |
40 (100%) |
39 (97.5%) |
0 |
| Anti-dsDNA antibody, (%) | 18 (45.0%) | 14 (35.0%) | 0 |